ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Multimodal Japanese-style acupuncture and moxibustion for taxane-related chemotherapy-induced peripheral neuropathy in breast cancer survivors.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTaxane-related chemotherapy-induced peripheral neuropathy (CIPN) is highly prevalent among breast cancer survivors and significantly impairs quality of life, yet established treatments are lacking. This study investigated the preliminary efficacy and safety of multimodal Japanese-style acupuncture and moxibustion (MJAM)-a program combining filiform needle acupuncture, non-insertive needle (Teishin) therapy, motion-style acupuncture, indirect moxibustion, hot pack application, and self-care instruction-for taxane-related CIPN.
methodsIn this single-center, single-arm study, we enrolled breast cancer survivors who had completed curative treatment for stage I-III breast cancer at least 3 months previously and who had moderate-to-severe taxane-related CIPN pain (BPI item 5 score of 4 or greater) at the time of enrollment. Participants received 12 weekly sessions of a standardized MJAM program. The primary endpoint was the change in Brief Pain Inventory (BPI) item 5 (average pain) from baseline to week 16.
resultsBetween October 2022 and April 2024, 30 women (median age 58.0 years) were enrolled. Median time since chemotherapy completion was 2.47 years. Mean baseline BPI item 5 score was 5.3 (SD 1.7). Twenty-eight participants (93.3%) completed the treatment. Nine participants (30.0%) experienced mild (grade 1) adverse events. BPI item 5 scores significantly decreased over time. Changes from baseline were -0.1 (95%CI, -0.6 to 0.3; p = 0.56) at week 4, -0.7 (95%CI, -1.2 to -0.2; p = 0.008) at week 8, -1.1 (95%CI, -1.7 to -0.6; p = 0.0003) at week 12, and -1.2 (90%CI, -1.7 to -0.8; p < 0.0001) at week 16.
conclusionsMJAM was safe, feasible, and associated with a reduction in pain in breast cancer survivors with persistent taxane-related CIPN. A confirmatory randomized clinical trial is warranted.
trial registrationUMIN-CTR UMIN000048478.
Indexed as
Identifiers
42768220What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.